Skip to main content

Advertisement

SpringerLink
Log in

The role of C-reactive protein as a prognostic indicator in advanced cancer

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

C-reactive protein (CRP) is a nonspecific but sensitive marker of inflammation. Interleukin-6 (IL-6), IL-1, and tumor necrosis factor á induce the synthesis of CRP in hepatocytes. Increased CRP level is considered to be an important risk factor for atherosclerosis, myocardial infarction, peripheral vascular disease, and ischemic stroke. It is positively correlated with weight loss, anorexiacachexia syndrome, extent of disease, and recurrence in advanced cancer. Its role as a predictor of survival has been shown in multiple myeloma, melanoma, lymphoma, ovarian, renal, pancreatic, and gastrointestinal tumors. Measurement of CRP is simple, cheap, and routine and provides valuable information in palliative care.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Geissbuhler P, Mermillod B, Rapin CH: Elevated serum vitamin B12 levels associated with CRP as a predictive factor of mortality in palliative care cancer patients: a prospective study over five years. J Pain Symptom Manage 2000, 20:93–103. This interesting study indicates that an elevated serum B12 level is a predictive factor for mortality, independent of CRP and other factors, in palliative care.

    Article  PubMed  CAS  Google Scholar 

  2. Du Clos TW: Function of C-reactive protein. Ann Med 2000, 32:274–278.

    PubMed  Google Scholar 

  3. Jaye DL, Waites KB: Clinical applications of C-reactive protein in pediatrics. Pediatr Infect Dis J 1997, 16:735–746.

    Article  PubMed  CAS  Google Scholar 

  4. Yeh ET, Anderson HV, Pasceri V, Willerson JT: C-reactive protein: linking inflammation to cardiovascular complications. Circulation 2001, 104:974–975. This is an interesting article discussing the role of inflammation and CRP as predisposing to cardiovascular events.

    PubMed  CAS  Google Scholar 

  5. Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999, 340:448–454.

    Article  PubMed  CAS  Google Scholar 

  6. Morrow DA, Ridker PM: C-reactive protein, inflammation, and coronary risk. Med Clin North Am 2000, 84:149–161.

    Article  PubMed  CAS  Google Scholar 

  7. Di Napoli M, Papa F, Bocola V: C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke 2001, 32:917–924.

    PubMed  Google Scholar 

  8. Kushner I: C-reactive protein elevation can be caused by conditions other than inflammation and may reflect biologic aging. Cleve Clin J Med 2001, 68:535–537. s is an excellent article discussing the role of CRP as a predictor for both biologic aging and poor prognosis in many conditions.

    Article  PubMed  CAS  Google Scholar 

  9. Preston T, Fearon KC, McMillan DC, et al.: Effect of ibuprofen on the acute-phase response and protein metabolism in patients with cancer and weight loss. Br J Surg 1995, 82:229–234.

    Article  PubMed  CAS  Google Scholar 

  10. McMillan DC, Wigmore SJ, Fearon KC, et al.: A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer 1999, 79:495–500. s is an outstanding study comparing the combination of megestrol acetate and placebo with megestrol acetate and ibuprofen in the treatment of weight loss in patients with gastrointestinal cancer.

    Article  PubMed  CAS  Google Scholar 

  11. Falus A, Meretey K: Histamine: an early messenger in inflammatory and immune reactions. Immunol Today 1992, 13:154–156.

    Article  PubMed  CAS  Google Scholar 

  12. Rasmussen LA, Nielsen HJ, Sorensen S, et al.: Ranitidine reduces postoperative interleukin-6 induced C-reactive protein synthesis. J Am Coll Surg 1995, 181:138–144.

    PubMed  CAS  Google Scholar 

  13. Pelliniemi TT, Irjala K, Mattila K, et al.: Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood 1995, 85:765–771.

    PubMed  CAS  Google Scholar 

  14. Tartour E, Dorval T, Mosseri V, et al.: Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer 1994, 69:911–913.

    PubMed  CAS  Google Scholar 

  15. Legouffe E, Rodriguez C, Picot MC, et al.: C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin’s lymphoma. Leuk Lymphoma 1998, 31:351–357.

    PubMed  CAS  Google Scholar 

  16. Kodama J, Miyagi Y, Seki N, et al.: Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1999, 82:107–110. is an interesting study about the role of CRP in predicting survival.

    Article  PubMed  CAS  Google Scholar 

  17. Scambia G, Testa U, Benedetti PP, et al.: Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer 1995, 71:354–356.

    PubMed  CAS  Google Scholar 

  18. Ljungberg B, Grankvist K, Rasmuson T: Serum acute phase reactants and prognosis in renal cell carcinoma. Cancer 1995, 76:1435–1439.

    Article  PubMed  CAS  Google Scholar 

  19. Huang A, Tsavellas G: Acute-phase protein, survival and tumour recurrence in patients with colorectal cancer. Br J Surg 2001, 88:1128.

    Article  PubMed  CAS  Google Scholar 

  20. O’Gorman P, McMillan DC, McArdle CS: Prognostic factors in advanced gastrointestinal cancer patients with weight loss. Nutr Cancer 2000, 37:36–40.

    Article  PubMed  CAS  Google Scholar 

  21. Falconer JS, Fearon KC, Ross JA, et al.: Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 1995, 75:2077–2082.

    Article  PubMed  CAS  Google Scholar 

  22. Barber MD, Fearon KC, Ross JA: Relationship of serum levels of interleukin-6, soluble interleukin-6 receptor and tumour necrosis factor receptors to the acute-phase protein response in advanced pancreatic cancer. Clin Sci 1999, 96:83–87.

    Article  PubMed  CAS  Google Scholar 

  23. Nozoe T, Matsumata T, Kitamura M, Sugimachi K: Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 1998, 176:335–338.

    Article  PubMed  CAS  Google Scholar 

  24. Miyata Y, Koga S, Nishikido M, et al.: Predictive values of acute phase reactants, basic fetoprotein, and immunosuppressive acidic protein for staging and survival in renal cell carcinoma. Urology 2001, 58:161–164.

    Article  PubMed  CAS  Google Scholar 

  25. Vesole DH, Tricot G, Jagannath S, et al.: Autotransplants in multiple myeloma: what have we learned? Blood 1996, 88:838–847.

    PubMed  CAS  Google Scholar 

  26. Bataille R, Boccadoro M, Klein B, et al.: C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992, 80:733–737.

    PubMed  CAS  Google Scholar 

  27. Mestries JC, Kruithof EK, Gascon MP, et al.: In vivo modulation of coagulation and fibrinolysis by recombinant glycosylated human interleukin-6 in baboons. Eur Cytokine Netw 1994, 5:275–281.

    PubMed  CAS  Google Scholar 

  28. Cermak J, Key NS, Bach RR, et al.: C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993, 82:513–520.

    PubMed  CAS  Google Scholar 

  29. Harris TB, Ferrucci L, Tracy RP, et al.: Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999, 106:506–512.

    Article  PubMed  CAS  Google Scholar 

  30. Baeuerle PA, Rupec RA, Pahl HL: Reactive oxygen intermediates as second messengers of a general pathogen response. Pathol Biol 1996, 44:29–35.

    PubMed  CAS  Google Scholar 

  31. Nelson KA, Walsh D, Sheehan FA: The cancer anorexiacachexia syndrome. J Clin Oncol 1994, 12:213–225.

    PubMed  CAS  Google Scholar 

  32. Walsh D, Donnelly S, Rybicki L: The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. Support Care Cancer 2000, 8:175–179. s is an excellent comprehensive prospective analysis of symptoms in 1000 patients with advanced cancer.

    Article  PubMed  CAS  Google Scholar 

  33. Strassmann G, Fong M, Kenney JS, Jacob CO: Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 1992, 89:1681–1684.

    PubMed  CAS  Google Scholar 

  34. Tisdale MJ: Wasting in cancer. J Nutr 1999, 129:243S-246S.

    PubMed  CAS  Google Scholar 

  35. Tempfer C, Zeisler H, Sliutz G, et al.: Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol Oncol 1997, 66:27–30.

    Article  PubMed  CAS  Google Scholar 

  36. Oka M, Yamamoto K, Takahashi M, et al.: Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res 1996, 56:2776–2780.

    PubMed  CAS  Google Scholar 

  37. Warren RS, Starnes HF Jr, Gabrilove JL, et al.: The acute metabolic effects of tumor necrosis factor administration in humans. Arch Surg 1987, 122:1396–1400.

    PubMed  CAS  Google Scholar 

  38. McMillan DC, Scott HR, Watson WS, et al.: Longitudinal study of body cell mass depletion and the inflammatory response in cancer patients. Nutr Cancer 1998, 31:101–105.

    Article  PubMed  CAS  Google Scholar 

  39. Kato K, Hitsuda Y, Kawasaki Y, et al.: The value of serum C-reactive protein as a survival determinant in patients with advanced non-small-cell lung cancer. Nihon Kokyuki Gakkai Zasshi 2000, 38:575–580.

    PubMed  CAS  Google Scholar 

  40. Wu CW, Wang SR, Chao MF, et al.: Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol 1996, 91:1417–1422.

    PubMed  CAS  Google Scholar 

  41. Nomura K, Noguchi Y, Matsumoto A: Stimulation of decreased lipoprotein lipase activity in the tumor-bearing state by the antihyperlipidemic drug bezafibrate. Surg Today 1996, 26:89–94.

    Article  PubMed  CAS  Google Scholar 

  42. Ohara M, Tsutsumi K, Ohsawa N: Suppression of carcass weight loss in cachexia in rats bearing Leydig cell tumor by the novel compound NO-1886, a lipoprotein lipase activator. Metabolism 1998, 47:101–105.

    PubMed  CAS  Google Scholar 

  43. Tsujimoto S, Kawamura I, Inami M, et al.: Cachexia induction by EL-4 lymphoma in mice and possible involvement of impaired lipoprotein lipase activity. Anticancer Res 2000, 20:3111–3116.

    PubMed  CAS  Google Scholar 

  44. Lavabre-Bertrand T, Exbrayat C, Liautard J, et al.: Detection of membrane and soluble interleukin-6 receptor in lymphoid malignancies. Br J Haematol 1995, 91:871–877.

    PubMed  CAS  Google Scholar 

  45. Yokoyama A, Kohno N, Hirasawa Y, et al.: Evaluation of soluble IL-6 receptor concentration in serum and epithelial lining fluid from patients with interstitial lung diseases. Clin Exp Immunol 1995, 100:325–329.

    Article  PubMed  CAS  Google Scholar 

  46. Baumann H, Gauldie J: The acute phase response. Immunol Today 1994, 15:74–80.

    Article  PubMed  CAS  Google Scholar 

  47. Wigmore SJ, McMahon AJ, Sturgeon CM, Fearon KC: Acutephase protein response, survival and tumour recurrence in patients with colorectal cancer. Br J Surg 2001, 88:255–260. s important study investigates the prognostic significance of a preoperative and postoperative acute phase protein response in relation to disease-specific mortality rate.

    Article  PubMed  CAS  Google Scholar 

  48. Cooper EH, Stone J: Acute phase reactant proteins in cancer. Adv Cancer Res 1979, 30:1–44.

    Article  PubMed  CAS  Google Scholar 

  49. McMillan DC, Wotherspoon HA, Fearon KC, et al.: A prospective study of tumor recurrence and the acute-phase response after apparently curative colorectal cancer surgery. Am J Surg 1995, 170:319–322.

    Article  PubMed  CAS  Google Scholar 

  50. Fujikawa K, Matsui Y, Oka H, et al.: Serum C-reactive protein level and the impact of cytoreductive surgery in patients with metastatic renal cell carcinoma. J Urol 1999, 162:1934–1937.

    Article  PubMed  CAS  Google Scholar 

  51. Earlam S, Glover C, Fordy C, et al.: Relation between tumor size, quality of life, and survival in patients with colorectal liver metastases. J Clin Oncol 1996, 14:171–175.

    PubMed  CAS  Google Scholar 

  52. Goransson J, Jonsson S, Lasson A: Pre-operative plasma levels of C-reactive protein, albumin and various plasma protease inhibitors for the pre-operative assessment of operability and recurrence in cancer surgery. Eur J Surg Oncol 1996, 22:607–617.

    Article  PubMed  CAS  Google Scholar 

  53. Steinshamn S, Brekke OL, Waage A: Soluble tumour necrosis factor receptors, tumour necrosis factor and interleukin-6 in serum in granulocytopenic patients with fever. Br J Haematol 1995, 89:719–724.

    Article  PubMed  CAS  Google Scholar 

  54. Kallio R, Bloigu A, Surcel HM, Syrjala H: C-reactive protein and erythrocyte sedimentation rate in differential diagnosis between infections and neoplastic fever in patients with solid tumours and lymphomas. Support Care Cancer 2001, 9:124–128.

    Article  PubMed  CAS  Google Scholar 

  55. Heney D, Lewis IJ, Evans SW, et al.: Interleukin-6 and its relationship to C-reactive protein and fever in children with febrile neutropenia. J Infect Dis 1992, 165:886–890.

    PubMed  CAS  Google Scholar 

  56. Economos K, Lucci JAIII, Richardson B, et al.: The effect of naproxen on fever in patients with advanced gynecologic malignancies. Gynecol Oncol 1995, 56:250–254.

    Article  PubMed  CAS  Google Scholar 

  57. Ueno H, Okada S, Okusaka T, et al.: Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology 2000, 59:296–301.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Taussig Cancer Center, The Cleveland Clinic Foundation, M76, 9500 Euclid Avenue, 44195, Cleveland, OH, USA

    Fade Aziz Mahmoud MD & Nilo I. Rivera MD

Authors
  1. Fade Aziz Mahmoud MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nilo I. Rivera MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mahmoud, F.A., Rivera, N.I. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 4, 250–255 (2002). https://doi.org/10.1007/s11912-002-0023-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-002-0023-1

Keywords

Search

Navigation